These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 34593621)

  • 21. Peripheral blood lymphocyte subsets predict the efficacy of TACE with or without PD-1 inhibitors in patients with hepatocellular carcinoma: a prospective clinical study.
    Wang H; Huang H; Liu T; Chen Y; Li J; He M; Peng J; Liang E; Li J; Liu W
    Front Immunol; 2024; 15():1325330. PubMed ID: 38404585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
    Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
    Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact of Chemoembolic Regimen on Immune Cell Recruitment and Immune Checkpoint Marker Expression following Transcatheter Arterial Chemoembolization in a VX2 Rabbit Liver Tumor Model.
    Berz AM; Santana JG; Iseke S; Gross M; Pekurovsky V; Laage Gaupp F; Savic LJ; Borde T; Gottwald LA; Boustani AM; Gebauer B; Lin M; Zhang X; Schlachter T; Madoff DC; Chapiro J
    J Vasc Interv Radiol; 2022 Jul; 33(7):764-774.e4. PubMed ID: 35346859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
    Wang YY; Yang X; Wang YC; Long JY; Sun HS; Li YR; Xun ZY; Zhang N; Xue JN; Ning C; Zhang JW; Zhu CP; Zhang LH; Yang XB; Zhao HT
    World J Gastroenterol; 2023 Mar; 29(10):1614-1626. PubMed ID: 36970591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
    Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety.
    Wei W; Jian PE; Li SH; Guo ZX; Zhang YF; Ling YH; Lin XJ; Xu L; Shi M; Zheng L; Chen MS; Guo RP
    Cancer Commun (Lond); 2018 Oct; 38(1):61. PubMed ID: 30305149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
    Zou X; Xu Q; You R; Yin G
    Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DEB TACE for Intermediate and advanced HCC - Initial Experience in a Brazilian Cancer Center.
    Luz JH; Luz PM; Martin HS; Gouveia HR; Levigard RB; Nogueira FD; Rodrigues BC; de Miranda TN; Mamede MH
    Cancer Imaging; 2017 Feb; 17(1):5. PubMed ID: 28166821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 25-OH-vitamin D deficiency identifies poor tumor response in hepatocellular carcinoma treated with transarterial chemoembolization.
    Wu YQ; Fan WZ; Xue M; Guo J; Wei JL; Wang Y; Yao W; Zhao Y; Li JP
    Clin Transl Oncol; 2020 Jan; 22(1):70-80. PubMed ID: 31183764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
    Li J; Wang N; Shi C; Liu Q; Song J; Ye X
    J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma.
    Luo C; Xin H; Yin D; Zhao T; Hu Z; Zhou Z; Sun R; Yao N; Sun Q; Fan J; Huang X; Zhou J; Zhou S
    Aging (Albany NY); 2021 Jun; 13(11):15126-15138. PubMed ID: 34081621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients.
    Gomes AS; Monteleone PA; Sayre JW; Finn RS; Sadeghi S; Tong MJ; Britten CD; Busuttil RW
    AJR Am J Roentgenol; 2017 Oct; 209(4):722-732. PubMed ID: 28705059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
    Wu Y; Fan W; Xue M; Zhong B; Zhang S; Wang Y; Yao W; Zhao Y; Li J
    Oncologist; 2019 Dec; 24(12):e1489-e1495. PubMed ID: 31249138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization.
    Guo M; Qi F; Rao Q; Sun J; Du X; Qi Z; Yang B; Xia J
    Front Immunol; 2021; 12():754961. PubMed ID: 34691076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel prognostic signature based on immunogenic cell death score predicts outcomes and response to transcatheter arterial chemoembolization and immunotherapy in hepatocellular carcinoma.
    Zhang Y; Yang J; Xie S; Chen H; Zhong J; Lin X; Yu Z; Xia J
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11411-11429. PubMed ID: 37382674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Postoperative adjuvant arterial chemoembolization improves the survival of hepatitis B virus-related hepatocellular carcinoma: a retrospective control study.
    Li F; Guo Z; Zhang Y; Wang H; Zhang X; Si T; Yu H; Qi L
    Ir J Med Sci; 2015 Dec; 184(4):753-9. PubMed ID: 24972992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.